3D-Printed Self-Emulsifying Drug Delivery Systems (SEDDS) for Personalized Oral Drug Delivery: Manufacturing Challenges and Regulatory Perspectives

Self-Emulsifying Drug Delivery Systems (SEDDS) are widely used to enhance the oral bioavailability of poorly water-soluble Biopharmaceutics Classification System (BCS) Class II and IV drugs, but conventional liquid-filled capsule formats offer limited flexibility for individualized dosing. Three-dimensional (3D) printing has emerged as a promising technology for producing patient-specific dosage forms with precise control over dose, geometry, and release profile, and its convergence with SEDDS technology represents a novel and largely underexplored area of pharmaceutical research. This review examines the principal additive manufacturing platforms applied to SEDDS integration, including semi-solid extrusion, vat photopolymerization (stereolithography/digital light processing), fused deposition modeling, and inkjet/binder jetting, along with the strategies used to render inherently liquid or semi-solid SEDDS formulations printable. The personalization advantages of this approach, including precise dose titration, polypharmacy consolidation, and pediatric and geriatric dosing applications, are discussed alongside the significant manufacturing challenges that remain, including thermal and photochemical stability, rheological constraints, content uniformity, storage stability, and scale-up limitations. Particular attention is given to the regulatory landscape governing this emerging product class, where existing guidance remains centered on centralized, fixed-formulation manufacturing and has not yet established harmonized, product-specific standards for feedstock qualification, process validation, or decentralized point-of-care production. Continued progress in both formulation science and regulatory framework development will be necessary to translate 3D-printed SEDDS from proof-of-concept research toward clinical application in truly individualized oral drug therapy.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-17
DOI
https://doi.org/10.5281/zenodo.24311198
Primary Topic
Additive Manufacturing and 3D Printing Technologies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

3D-Printed Self-Emulsifying Drug Delivery Systems (SEDDS) for Personalized Oral Drug Delivery: Manufacturing Challenges and Regulatory Perspectives

Priyadharshini R.
1 links
Zenodo (CERN European Organization for Nuclear Research)
Additive Manufacturing and 3D Printing Technologies
article

3D-Printed Self-Emulsifying Drug Delivery Systems (SEDDS) for Personalized Oral Drug Delivery: Manufacturing Challenges and Regulatory Perspectives

Priyadharshini R.
article en

Abstract

Self-Emulsifying Drug Delivery Systems (SEDDS) are widely used to enhance the oral bioavailability of poorly water-soluble Biopharmaceutics Classification System (BCS) Class II and IV drugs, but conventional liquid-filled capsule formats offer limited flexibility for individualized dosing. Three-dimensional (3D) printing has emerged as a promising technology for producing patient-specific dosage forms with precise control over dose, geometry, and release profile, and its convergence with SEDDS technology represents a novel and largely underexplored area of pharmaceutical research. This review examines the principal additive manufacturing platforms applied to SEDDS integration, including semi-solid extrusion, vat photopolymerization (stereolithography/digital light processing), fused deposition modeling, and inkjet/binder jetting, along with the strategies used to render inherently liquid or semi-solid SEDDS formulations printable. The personalization advantages of this approach, including precise dose titration, polypharmacy consolidation, and pediatric and geriatric dosing applications, are discussed alongside the significant manufacturing challenges that remain, including thermal and photochemical stability, rheological constraints, content uniformity, storage stability, and scale-up limitations. Particular attention is given to the regulatory landscape governing this emerging product class, where existing guidance remains centered on centralized, fixed-formulation manufacturing and has not yet established harmonized, product-specific standards for feedstock qualification, process validation, or decentralized point-of-care production. Continued progress in both formulation science and regulatory framework development will be necessary to translate 3D-printed SEDDS from proof-of-concept research toward clinical application in truly individualized oral drug therapy.

Zenodo (CERN European Organization for Nuclear Research)
University of Nottingham (GB)
Good health and well-being
Additive Manufacturing and 3D Printing Technologies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon